Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 6
2005 9
2006 10
2007 16
2008 21
2009 25
2010 15
2011 32
2012 35
2013 41
2014 47
2015 35
2016 40
2017 31
2018 41
2019 38
2020 48
2021 26
2022 18
2023 24
2024 29
2025 38
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

587 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF, Cockrill BA. Ruopp NF, et al. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. JAMA. 2022. PMID: 35412560 Review.
Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan a …
Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (silden …
Ambrisentan.
[No authors listed] [No authors listed] 2017 Sep 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Sep 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643986 Free Books & Documents. Review.
Ambrisentan is an endothelin receptor antagonist used in the therapy of pulmonary arterial hypertension (PAH). Ambrisentan has been associated with a low rate of serum enzyme elevations during therapy, but has yet to be implicated in cases of clinically apparent acu …
Ambrisentan is an endothelin receptor antagonist used in the therapy of pulmonary arterial hypertension (PAH). Ambrisentan has …
Ambrisentan.
[No authors listed] [No authors listed] 2025 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 39836810 Free Books & Documents. Review.
No information is available on the use of ambrisentan during breastfeeding. Because ambrisentan is more than 99% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ambrisentan …
No information is available on the use of ambrisentan during breastfeeding. Because ambrisentan is more than 99% bound to plas …
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination t …
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization funct …
Ambrisentan.
Croxtall JD, Keam SJ. Croxtall JD, et al. Drugs. 2008;68(15):2195-204. doi: 10.2165/00003495-200868150-00008. Drugs. 2008. PMID: 18840007 Review.
At week 12, WHO functional class distribution was significantly improved with once-daily ambrisentan 5 mg, and Borg dyspnoea scores were significantly improved with ambrisentan 2.5-10 mg versus placebo in combined data from the ARIES-1 and -2 trials. ...One-year sur …
At week 12, WHO functional class distribution was significantly improved with once-daily ambrisentan 5 mg, and Borg dyspnoea scores w …
Endothelin.
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Davenport AP, et al. Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. Pharmacol Rev. 2016. PMID: 26956245 Free PMC article. Review.
Highly selective peptide ETA and ETB antagonists and ETB agonists together with radiolabeled analogs have accurately delineated endothelin pharmacology in humans and animal models, although surprisingly no ETA agonist has been discovered. ET antagonists (bosentan, ambrisentan …
Highly selective peptide ETA and ETB antagonists and ETB agonists together with radiolabeled analogs have accurately delineated endothelin p …
Ambrisentan.
Frampton JE. Frampton JE. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):215-26. doi: 10.2165/11207340-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21623643 Review.
Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pulmonary arterial hypertension (PAH). ...Ambrisentan was associated with a low risk of clinical worsening and of death. Ambrisentan …
Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pul …
Ambrisentan (Myogen).
Billman GE. Billman GE. Curr Opin Investig Drugs. 2002 Oct;3(10):1483-6. Curr Opin Investig Drugs. 2002. PMID: 12431023 Review.
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan …
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BAS …
Ambrisentan.
Newman JH, Kar S, Kirkpatrick P. Newman JH, et al. Nat Rev Drug Discov. 2007 Sep;6(9):697-8. doi: 10.1038/nrd2402. Nat Rev Drug Discov. 2007. PMID: 17907344 No abstract available.
Pulmonary arterial hypertension.
Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, Humbert M, Simonneau G, Sitbon O. Montani D, et al. Orphanet J Rare Dis. 2013 Jul 6;8:97. doi: 10.1186/1750-1172-8-97. Orphanet J Rare Dis. 2013. PMID: 23829793 Free PMC article. Review.
Several specific therapeutic agents were developed for the medical management of PAH including prostanoids (epoprostenol, trepoprostenil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan) and phosphodiesterase type 5 inhibitors (sildenafil, tadalafil). Thi …
Several specific therapeutic agents were developed for the medical management of PAH including prostanoids (epoprostenol, trepoprostenil, il …
587 results